UPDATE 1-
DaVita quarterly profit down slightlyThu Nov 1, 2007 4:59pm EDT
(Adds CFO change, details on results, forecast, stock activity)
LOS ANGELES, Nov 1 (Reuters) - DaVita Inc (DVA.N: Quote, Profile, Research), the biggest owner of dialysis clinics in the United States, said on Thursday quarterly net income was down from a year ago and that 2008 operating income could be at the low end of its forecast.
The company also said Mark Harrison would step down as chief financial officer effective Nov 30.
Jim Hilger, the company's vice president and controller, will assume the additional role of acting chief financial officer.
DaVita had third-quarter net income of $94.5 million, or 88 cents per share, compared with net income of $94.9 million, or 90 cents per share, in the year-earlier quarter.
The company, based in El Segundo, California, said adjusted earnings for the quarter were 83 cents per share, a penny short of analysts' average estimate, according to Reuters Estimates.
Net operating revenue was up slightly to $1.3 billion from $1.2 billion a year ago.
Wall Street has been closely monitoring how a controversy over the safety of anemia drugs will impact DaVita, which runs more than 1,300 dialysis clinics in the United States.
The U.S. Food and Drug Administration earlier this year put its strongest black box warning on the drugs, made by Amgen Inc (AMGN.O: Quote, Profile, Research) and Johnson & Johnson (JNJ.N: Quote, Profile, Research), and the government agency overseeing Medicare and Medicaid -- which covers many dialysis patients - said it would pare coverage for the drugs.
Sales of Amgen's Epogen, used to treat anemia in people with kidney disease, fell 5 percent to $602 million in the third quarter.
DaVita forecast fourth quarter operating income in the range of $190 million to $200 million. It also narrowed its forecast for operating income for 2007 to a range of $800 million to $810 million.
It maintained its operating income guidance for 2008, excluding the impact of any potential Medicare legislation, at $790 million to $850 million, but said it now expects it to be at the lower end of the range.
Shares of DaVita closed up 26 cents at $65.45 on the New York Stock Exchange before the company issued its results. (Reporting by Lisa Baertlein)
http://www.reuters.com/article/marketsNews/idUSN0158818320071101